Gene expression disparity in giant cell tumor of bone
- 26 Downloads
Abstract
The aim of this paper was to study the differential gene expression of giant cell tumor of bone (GCTB) by gene chip technology. Total RNA of 8 fresh GCTB specimens (Jaffe I:6 cases, II:1 case, III:1 case; Campanacci I:6 cases, II:1 case, III:1 case; Enneking Staging G0T1−2M0, 5 cases, G1T1−2M0: 2 cases, G1T2M0: 1 case) and 4 normal bony callus specimens (the control group) were extracted and purified to get mRNA and then reverse transcribed to complementary DNA, respectively. Microarray screening with a set of 8064 human cDNA genes was conducted to analyze the difference among the samples and the control. The hybridization signals were scanned. The gene expression disparity between the GCTB samples and normal bony callus was significantly different (P < 0.01), and the disparity of over 5-fold was found in 47 genes in the GCTB specimens, with 25 genes up-regulated and 22 down-regulated including the extracellular matrix and transforming-related genes, oncogene and its homolog genes, cytokine and its receptor genes. Specific gene spectrum associated with GCTB can be identified by cDNA microarray, which will be the foundation of progressive etiology elucidation, diagnosis and treatment of GCTB.
Keywords
giant cell tumor of bone gene microarray, cDNAPreview
Unable to display preview. Download preview PDF.
References
- 1.Tubbs W S, Brown L R, Beabout J W, Rock M G, Unni K K. Benign giant-cell tumor of bone with pulmonary metastases: clinical findings and radiologic appearance of metastases in 13 cases. AJR, 1992, 158(3): 331–334PubMedGoogle Scholar
- 2.Sung H W, Kuo D P, Shu W P, Chai Y B, Liu C C, Li S M. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am, 1982, 64(5): 755–761PubMedGoogle Scholar
- 3.Prosser G H, Baloch K G, Tillman R M, Carter S R, Grimer R J. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res, 2005, 435 (6): 211–218PubMedCrossRefGoogle Scholar
- 4.Ladanyi M, Tragano F, Huvos A, Benign metastasizing giant cell tumours of bone. Cancer, 1989, 64(7): 1521–1526PubMedCrossRefGoogle Scholar
- 5.Tian B L, Wen J M, Zhang M, Xie D, Xu R B, Luo C J. The expression of ADAM12 (meltrin alpha) in human giant cell tumours of bone. Mol Pathol, 2002, 55(6): 394–397PubMedCrossRefGoogle Scholar
- 6.Kumta S M, Huang L, Cheng Y Y, Chow LT C, Lee K M, Zheng M H. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci, 2003, 73(11): 1427–1436PubMedCrossRefGoogle Scholar
- 7.Welford S M, Gregg J, Chen E, Garrison D, Sorensen P H, Denny C T, Nelson S F. Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization. Nucleic Acids Res, 1998, 26(12): 3059–3065PubMedCrossRefGoogle Scholar
- 8.Li D P, Wang K, Dai Y, LV T Y. Gene Expression Profiling on Acute Rejected Transplant Kidneys with Microarray. J Huazhong Univ Sci Technol (Med Sci). 2008, 28(2): 136–139Google Scholar
- 9.Logar D B, Komadina R, Prezelj J, Ostanek B, Trost Z, Marc J. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab, 2007, 25(4): 219–225PubMedCrossRefGoogle Scholar
- 10.Lacey D L, Timms E, Tan H L, Kelley M J, Dunstan C R, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle W J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93(2): 165–176PubMedCrossRefGoogle Scholar
- 11.Kong Y Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch E R, Van G, Nguyen L T, Ohashi P S, Lacey D L, Fish E, Boyle W J, Penninger J M. Activated T cells regulate bone loss and joint destuction in adjuvant arthritis through osteoprotegerin ligand. Nature, 1999, 402(6759): 304–309PubMedCrossRefGoogle Scholar
- 12.Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner E F, Taniguchi T. RANKL maintaims bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature, 2002, 418 (6882): 744–749CrossRefGoogle Scholar
- 13.Guenther R, Krenn V, Morawietz L, Dankof A, Melcher I, Schaser K D, Kasper H U, Kuban R J, Ungethüm U, Sers C. Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol Res Pract, 2005, 201(10): 649–663PubMedCrossRefGoogle Scholar
- 14.Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop, 2004, 7(424): 221–226Google Scholar
- 15.Lackman R D, Hosalkar H S, Ogilvie C M, Torbert J T, Fox E J. Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res, 2005, 438(9): 123–127PubMedCrossRefGoogle Scholar
- 16.Lausten G S, Jensen P K, Schiødt T, Lund B. Local recurrences in giant cell tumour of bone: long-term follow up of 31 cases. Int Orthop, 1996, 20(3): 172–176PubMedCrossRefGoogle Scholar
- 17.Ghert M A, Rizzo M, Harrelson J M, Scully S P. Giant cell tumor in the appendicular skeleton, Clin Orthop Relat Res, 2002, 400(7): 201–210PubMedCrossRefGoogle Scholar